Empagliflozin to Prevent Post-Operative Atrial Fibrillation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 492 participants.
Also called NCT06124937
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 492 participants
- Registry
-
NCT06124937
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Iran
- Registry status
- Unknown status
Technical summary
Registry record NCT06124937. Randomized; quadruple masking; primary purpose prevention. Start 2023-11-07 (actual); primary completion 2024-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Empagliflozin to Prevent Post-Operative Atrial Fibrillation
- Acronym
- EMPOAF
- Condition
- Post-operative Atrial Fibrillation
- Intervention (Drug)
- Empagliflozin 10 MG
- Intervention (Drug)
- Placebo
- Lead sponsor
- Rajaie Cardiovascular Medical and Research Center
- Collaborator
- Tehran Heart Center
Record details
- Record id
cardio:ct-nct06124937- Content hash
48b16191b64244c3b4cb6b41a2f2e456decdd83169ebbc6522d6c2bebe7819c2